BioPharma From curing cancer to saving troubled LA Times, biotech billionaire Soon-Shiong has grand plans By Emily Willingham
BioPharma Soon-Shiong’s new cancer vaccine is the “culmination” of NantWorks’ science By Juliet Preston
Top Story Morning Read: Soon-Shiong shares good news on Adenovirus vaccine, Olympus settles kickback charges for $306M By Neil Versel
BioPharma, Diagnostics Soon-Shiong’s NantWorks invests $50M in Precision Biologics By Meghana Keshavan
Pharma, Startups Patrick Soon-Shiong startup NantPharma building out another Amgen cancer asset By Meghana Keshavan
Health IT, BioPharma Allscripts invests $200M in Soon-Shiong’s NantHealth in software integration deal (updated) By Neil Versel
Startups, BioPharma Soon-Shiong outfit NantCell raises $75M; focus is on cancer immunotherapy By Meghana Keshavan
Top Story Topics on this week’s MedHeads: Patrick Soon-Shiong, our site redesign & more of the week that was By Nicole Oran
